Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

AUGUST 23, 2021

Oxford Cannabinoid Technologies Holdings plc. Strict cash management controls are in operation across all areas of expenditure, whereby all budgeted central costs have been reviewed with measures agreed to reduce these wherever possible, in order to maximise the Group’s financial resources available for its drug development programmes.

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. 561-627-9455.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

MARCH 25, 2020

OTCQB: AXIM) (“AXIM® Biotech” or “AXIM”) has completed the acquisition of leading oncology research and development company Sapphire Biotech, Inc. (“Sapphire”). Valencia has stewarded Sapphire in the development of its unique patent-pending pipeline.

Research and Development 59

Research and Development Supply Chain Pharmaceutical Clinical Trials 59

MMJ Recs

DECEMBER 28, 2023

In this article, we’ll talk about a few of the most common conditions for which medical marijuana is prescribed, exploring the growing body of research and real-world experiences that contribute to its acceptance as a viable therapeutic option. CBD, a non-psychoactive cannabinoid, has gained attention for its anti-anxiety effects.

Conditions 98

Conditions Chronic Pain Epilepsy Research and Development 98

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

MARCH 18, 2020

The company, a leader in hemp-derived CBD extract products, has created an internal research and development division led by a former healthcare executive to focus on the science of hemp-derived phytocannabinoids, terpenes and flavonoid compounds. Charlotte’s Web Holdings, Inc. CW Labs and have an additional office in Boulder, Colo.

Clinical Trials 59

Clinical Trials Research and Development Terpenes Hemp 59

The Cannigma

DECEMBER 14, 2021

Hexahydrocannabinol (HHC), which was patented in the late 1940s as a “therapeutic substance having marihuana activity,” is a cannabinoid that’s growing in popularity and availability. HHC was synthesized in Adams’ laboratory as part of research to understand the active compounds in the cannabis plant. HHC metabolism.

Research and Development 116

Research and Development Cannabinoids Clinical Trials THC 116

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. More than 8 percent of those surveyed also reported already using cannabinoids, with 54 percent noting a beneficial clinical effect.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

JANUARY 19, 2022

During his 24 years in Congress, Congressman Moran was recognized as a champion of innovative research and development in areas including healthcare and national security, environmental protection and sustainability, and international trade and fiscal responsibility. About IGC: India Globalization Capital, Inc.

Clinical Trials 52

Clinical Trials Research and Development Education Therapy 52

Cannabis Law Report

JUNE 17, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. Tucker has successfully advanced several programs through clinical development and regulatory approval. CAMBRIDGE, Mass.–(BUSINESS Dr. Tucker. “I

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

OCTOBER 15, 2021

At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). CAMBRIDGE, Mass.–(BUSINESS Poster Number: INFO37. 212-362-1200.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

JUNE 4, 2021

Dr. Titus has been involved in the development and investment of several industry-leading cannabis and industrial hemp businesses during his most recent career. Dr. Titus developed several prominent cannabis companies, including HempMeds, KannaLife Sciences Inc, and Kannaway, LLC.

Research and Development 105

Research and Development Seed-To-Sale Cannabinoids THC 105

Cannabis Law Report

JUNE 15, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials.

Pharmaceutical 82

Pharmaceutical Clinical Trials Research and Development Events 82

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.

Research and Development 117

Research and Development Education Agriculture Patients 117

The Cannigma

JUNE 15, 2021

Cannabidiol (CBD) belongs to a class of molecules called cannabinoids , which are produced almost exclusively in cannabis — hence the name. Both THC and CBD were first isolated in a laboratory in the early 1940s by American researcher Roger Adams. The two cannabinoids can also cause very different effects in other ways.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

MARCH 2, 2020

The government said it is working with industry to explore further ways to reduce costs and encourage more research into uninterrupted access to cannabis-based medicinal products where clinically appropriate. By October 29, less than five patients had successfully obtained medicinal cannabis. But we still have a long way to go.

Medicine 59

Medicine Research and Development Clinical Trials Patients 59

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

TheAnswerPage

JANUARY 11, 2022

and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ In addition, if clinicians are not well informed about the health effects of cannabinoid-based products, clinicians will not be able to optimally treat their patients. So, why did this educational gap develop?

Patients 98

Patients Education Marijuana Therapy 98

Kind Meds (Cannabis Education Blog)

JANUARY 9, 2019

GW Pharma carefully developed Epidiolex using cannabinoids to reduce the occurrence of seizures. Thanks to their diligence in perfecting the drug and ensuring its safety for intended use, the Drug Enforcement Agency scheduled Epidiolex under the lowest Schedule classification for controlled substances. Dravet Syndrome.

Research and Development 97

Research and Development Treatment Pharmaceutical Conditions 97

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease. Cost of revenue. . .

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

NOVEMBER 24, 2019

Recommendations for research. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. NICE has made research recommendations on the use of cannabis-based medicinal products for severe treatment-resistant epilepsy. the person’s clinical condition is stable. Tools and resources.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Cannabis Law Report

SEPTEMBER 24, 2019

The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. Nabilone is a medicine, taken as a capsule, that has been developed to act in a similar way to THC. What about other medical cannabis products? There are many different medical cannabis products.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

SEPTEMBER 3, 2019

TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that its subsidiary MediPharm Labs Australia Pty. BARRIE, Ontario, Sept. Australian Leadership Appointments.

Pharmaceutical 45

Pharmaceutical Extraction Research and Development Supply Chain 45

Cannabis Law Report

JANUARY 11, 2019

Furthermore, by redefining hemp to include its “extracts, cannabinoids and derivatives,” Congress explicitly removed popular hemp products – such as hemp-derived CBD — from the purview of the CSA. CBD has been found to be generally well tolerated with a good safety profile.”.

Hemp 49

Hemp CBD Law Seed-To-Sale 49

Peninsula Alternative Health

MAY 15, 2019

As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. However, because cannabinoids reduce seizures through numerous mechanisms of actions, possible drug interactions are still unclear.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

Cannabis Law Report

OCTOBER 22, 2021

The increasing research on medical marijuana shows its therapeutic value for a range of health conditions, including chronic pain, cancer, arthritis, diabetes, depression, anxiety, and many more. Currently, the two main cannabinoids from the marijuana plant that are of medical interest are THC and CBD.

Research and Development 52

Research and Development Pharmaceutical Marijuana Chronic Pain 52

Cannabis Law Report

OCTOBER 18, 2021

The increasing research on medical marijuana shows its therapeutic value for a range of health conditions, including chronic pain, cancer, arthritis, diabetes, depression, anxiety, and many more. Currently, the two main cannabinoids from the marijuana plant that are of medical interest are THC and CBD. BX-1: Bionorica SE.

Research and Development 52

Research and Development Pharmaceutical Chronic Pain Therapy 52

CannaMD

MARCH 8, 2021

Luckily, you know you can always count on CannaMD to provide the research you need to fight fire with fire! 1455 – and how YOU can fight back with research-based arguments! Authorizing the department to sample marijuana delivery devices from a dispensing facility to determine safety [p. What is Florida House Bill 1455?

THC 116

THC Research and Development Treatment Patients 116

Alchimia

FEBRUARY 1, 2022

CBD is one of the principal cannabinoids found in cannabis and, along with THC, one of its best-known compounds. The fact that this cannabinoid does not produce the psychoactive effect that we associate with cannabis does not mean that it is an innocuous substance , these concepts are often confused. Does CBD have any side effects?

CBD 52

CBD Epilepsy Research and Development Cannabinoids 52

Peninsula Alternative Health

MAY 15, 2019

As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. However, because cannabinoids reduce seizures through numerous mechanisms of actions, possible drug interactions are still unclear.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

The Cannigma

FEBRUARY 1, 2023

Before we dive into the research, here’s the lowdown: Important takeaway points on cannabis and cancer Your situation is unique. Even if a cannabinoid has shown promise on one cancer line, that doesn’t mean it will work for all cancers – even if it’s within the same organ system. 1 So can cannabis cure cancer?

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

NOVEMBER 24, 2021

Published by The Journal of Cannabis Research. However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

NOVEMBER 1, 2021

The Liver Meeting, which takes place virtually on November 12 – 15, 2021, brings together clinicians, associates, and scientists from around the world to exchange information on the latest research, discuss new developments in liver treatment and transplantation, and network with leading experts in the field of hepatology.

Clinical Trials 52

Clinical Trials Research and Development Treatment Business 52